Hybrid 2024 - The challenges associated with future viral vectors and genome editing approaches скачать в хорошем качестве

Hybrid 2024 - The challenges associated with future viral vectors and genome editing approaches

Next generations of gene & cell therapies Session 1: The challenges associated with future viral vectors and genome editing approaches. From the main challenges, avenues and prospects for new vectors to optimized delivery and safety, and tomorrow's genome-editing strategies. Overview: Oumeya Adjali, Inserm - Gene therapy using AAV viral vectors ; from vector engineering to preclinical evaluation Short talks: Ana Buj-Bello, Inserm - Next generation AAV vectors for gene therapy of muscle disorders Alexis Duvergé, CNRS - Specific Targeting of Cancer Cells by Lentiviral Vectors Maria Grazia Biferi, Spark Therapeutics - Targeting CNS with AAV in a large animal Anarita Miccio, Inserm - Genome editing approaches for beta-hemoglobinopathies Aurélie Bedel, Bordeaux University - How to secure CRISPR-Cas9 use? Stéphane Boissel, Sparing Vision - Pioneering Genomics to Save Sight Round table: Sitra Tauscher-Wisniewski, Novartis Anne Douar, Vivet Therapeutics Annarita Miccio, Inserm